A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer

  title={A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer},
  author={Naiyer A. Rizvi and Jeffrey S. Humphrey and Elizabeth A Ness and Michael D. Johnson and Elora Gupta and Kathleen Williams and D. J. Daly and Daryl S. Sonnichsen and Delina A Conway and John L. Marshall and Herbert I. Hurwitz},
  journal={Clinical Cancer Research},
  pages={1963 - 1970}
Purpose: BMS-275291 is a novel broad-spectrum inhibitor of matrix metalloproteinase (MMPs) rationally designed to spare a class of closely related metalloproteinases known as sheddases. Inadvertent sheddase inhibition is hypothesized to play a role in the dose-limiting joint toxicities occurring with hydroxamate-based MMP inhibitors. This trial was conducted to establish the recommended phase II dose; determine safety, toxicity, and pharmacokinetics of BMS-275291; and to assess potential… 

Figures and Tables from this paper

A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
Bone marker studies showed that baseline serum levels of N-telopeptide, osteocalcin, procollagen I NH2-terminal propeptide and PICP had prognostic significance for PFS and/or overall survival in HRPC patients with bone metastases.
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
BMS-275291 added to chemotherapy increases toxicity and does not improve survival in advanced NSCLC.
Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment
This study aimed to explain the MMP structure, regulatory mechanism, and carcinogenic effect, investigate the matrix metalloproteinase-inhibitors (MMPIs) that are currently used in clinical trials for cancer treatment; and summarize the trial results.
Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo.
In vivo testing revealed that MMP-inhibitors are useful tools in anticancer therapy reducing tumour size and invasion even without direct effects on cell survival.
Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.
Findings indicate that the selective COX-2 inhibitor, etodolac, suppresses liver metastasis by reducing MMP-9 activity.
Matrix metalloproteinase-2 as a target for head and neck cancer therapy
The current status of M MP-2 inhibitors as anticancer agents and their failure in the clinic is discussed in light of new data on the MMP-2s role as a cell surface transducer – data that may lead to the design and development of novel, Mmp-2-targeting inhibitors.
Bifunctional inhibitors of urokinase and metalloproteinase-9 for cancer treatment - in silico evaluation
Several hybrid molecules are created - in silico - several hybrid molecules that could inhibit both uPA and MMP-9, and the best hybrid (UI1xAGB) had theoretical affinities of Ki = 1.61-9 mol for M MP-9 and Ki =1.36- 9 mol for uPA.
Targeted therapies for non-small cell lung cancer.
The existing evidence of novel agents currently studied in clinical trials, focusing on epidermal growth factor receptor family inhibitors, angiogenesis inhibitors, cyclooxygenase-2 inhibitors, Bcl-2 targeted agents, protein kinase C inhibitors, proteasome inhibitors, farnesyl transferase inhibitors and retinoids are reviewed.
Phase 1/2 trial of BMS‐275291 in patients with human immunodeficiency virus‐related Kaposi sarcoma
The safety and efficacy of a novel, orally bioavailable MMP inhibitor, BMS‐275291, was evaluated in patients with human immunodeficiency virus‐associated KS and the correlation between changes in the percentage of apoptotic cells in tumor biopsies and response was explored.
Potential Clinical Applications of Matrix Metalloproteinase Inhibitors and their Future Prospects
The field of MMPIs is still expanding, and generation of highly effective and selective MMPI might be a promising direction of this research area.


Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
Marimastat was well absorbed from the gastrointestinal tract, with high levels of the study drug detected in plasma within hours after drug administration, and the dose-limiting toxicity was severe inflammatory polyarthritis, which seemed to be a cumulative toxicity.
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.
  • J. Nemunaitis, C. Poole, A. Millar
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1998
This combined analysis investigated the effect of marimastat, a specific inhibitor of matrix metalloproteinases, on markers of tumor progression measured in patients with advanced cancer. By defining
Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases
  • R. Scatena
  • Biology, Medicine
    Expert opinion on investigational drugs
  • 2000
The drug has been shown to inhibit tumour growth and angiogenesis in a variety of preclinical models, including cancer of colon, breast, lung and intriguingly in melanoma and glioma models, and is exploring the utility of prinomastat in ophthalmology and dermatology.
Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.
Data demonstrate that BMS-275291 inhibits MMP activities that contribute to tumor metastasis and angiogenesis.
Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor.
  • A. Lockhart, R. Braun, H. Hurwitz
  • Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
The wound angiogenesis assay used in this study was practical, well tolerated, and reproducible and warrants additional investigation in clinical trials of other antiangiogenic agents.
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
This is one of the first demonstrations of a therapeutic benefit for a matrix metalloproteinase inhibitor in cancer patients and the greatest benefit was observed in patients who had previously received chemotherapy.
Biology of TACE inhibition
Through a series of studies, it is shown that >80% of the unprocessed proTNFα is degraded intracellularly and appears to be transiently expressed on the cell surface.
A phase II trial of docetaxel in advanced non-small cell lung cancer.
Single-agent docetaxel appears to be active against both previously treated and untreated advanced NSCLC, and toxicity was acceptable but should be carefully monitored.
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
The results of this study provide no evidence to support a combination of marimastat with gemcitabine in patients with advanced pancreatic cancer and further studies of marIMastat as a maintenance treatment following a response or stable disease on gem citabine may be justified.
Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer.
  • M. Michael, B. Babić, F. Shepherd
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
The results support the evaluation of synthetic MMP inhibitors in patients with SCLC and show MMPs and TIMP expression did not differ significantly between stages.